ReproCell Stock

ReproCell Interest Expense

The Interest Expense of ReproCell (4978.T) as of Sep 4, 2026 is 64.72 M JPY. In the previous year, Interest Expense was 135.29 M JPY — a change of -52.16% (lower).

Interest Expense

64.72 MJPY

YoY

-52.16%

Last updated:

Interest Expense of ReproCell is 2026 64.72 M JPY. Interest Expense of ReproCell was 2025 135.29 M JPY. It decreases by -52.16% lower compared to the previous year.

The ReproCell Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2018
16.00 M JPY
Jan 1, 2019
104.78 M JPY
Jan 1, 2020
-49.86 M JPY
Jan 1, 2021
38.29 M JPY
Jan 1, 2022
-33.78 M JPY
Jan 1, 2023
106.06 M JPY
Jan 1, 2024
135.29 M JPY
Jan 1, 2025
64.72 M JPY
The ReproCell Interest Expense history
YEARInterest ExpenseYoY
64.72 MJPY-52.16%
135.29 MJPY+27.56%
106.06 MJPY-413.97%
-33.78 MJPY-188.22%
38.29 MJPY-176.80%
-49.86 MJPY-147.58%
104.78 MJPY+554.97%
16.00 MJPY-123.94%
-66.81 MJPY-65.25%
-192.23 MJPY-210.58%
173.84 MJPY+4,357.36%
3.90 MJPY
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Interest Expense of ReproCell is 64.72 M JPY in 2026.

Interest Expense of ReproCell changed from 135.29 M JPY to 64.72 M JPY, representing a -52.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense ReproCell since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's ReproCell historically and in real time.

Access this data via the Eulerpool API

Income Statement — ReproCell

All Key Metrics — ReproCell